263 related articles for article (PubMed ID: 25364393)
1. Targeting angiogenesis in advanced cervical cancer.
Eskander RN; Tewari KS
Ther Adv Med Oncol; 2014 Nov; 6(6):280-92. PubMed ID: 25364393
[TBL] [Abstract][Full Text] [Related]
2. Breaking down the evidence for bevacizumab in advanced cervical cancer: past, present and future.
Rodriguez-Freixinos V; Mackay HJ
Gynecol Oncol Res Pract; 2015; 2():8. PubMed ID: 27231568
[TBL] [Abstract][Full Text] [Related]
3. Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer.
Krill LS; Tewari KS
Expert Opin Pharmacother; 2015 Apr; 16(5):675-83. PubMed ID: 25643984
[TBL] [Abstract][Full Text] [Related]
4. Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology.
Eskander RN; Tewari KS
Future Oncol; 2015; 11(6):909-22. PubMed ID: 25760973
[TBL] [Abstract][Full Text] [Related]
5. A single-arm study evaluating bevacizumab, cisplatin, and paclitaxel followed by single-agent bevacizumab in Japanese patients with advanced cervical cancer.
Sugiyama T; Mizuno M; Aoki Y; Sakurai M; Nishikawa T; Ueda E; Tajima K; Takeshima N
Jpn J Clin Oncol; 2017 Jan; 47(1):39-46. PubMed ID: 27803033
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).
Grau JF; Farinas-Madrid L; Oaknin A
Int J Gynecol Cancer; 2020 Jan; 30(1):139-143. PubMed ID: 31645423
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review.
Aravantinos G; Pectasides D
J Ovarian Res; 2014; 7():57. PubMed ID: 24864163
[TBL] [Abstract][Full Text] [Related]
8. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.
Boussios S; Seraj E; Zarkavelis G; Petrakis D; Kollas A; Kafantari A; Assi A; Tatsi K; Pavlidis N; Pentheroudakis G
Crit Rev Oncol Hematol; 2016 Dec; 108():164-174. PubMed ID: 27931835
[TBL] [Abstract][Full Text] [Related]
9. Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition.
Minion LE; Tewari KS
Gynecol Oncol; 2018 Mar; 148(3):609-621. PubMed ID: 29666026
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).
Penson RT; Huang HQ; Wenzel LB; Monk BJ; Stockman S; Long HJ; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Method M; Michael H; Tewari KS
Lancet Oncol; 2015 Mar; 16(3):301-11. PubMed ID: 25638326
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in "real world" patients.
Godoy-Ortiz A; Plata Y; Alcaide J; Galeote A; Pajares B; Saez E; Alba E; Sánchez-Muñoz A
Clin Transl Oncol; 2018 Jul; 20(7):922-927. PubMed ID: 29222647
[TBL] [Abstract][Full Text] [Related]
12. Profile of bevacizumab and its potential in the treatment of cervical cancer.
Fisher CM; Schefter TE
Onco Targets Ther; 2015; 8():3425-31. PubMed ID: 26640382
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab for the treatment of cervical cancer.
Bizzarri N; Ghirardi V; Alessandri F; Venturini PL; Valenzano Menada M; Rundle S; Leone Roberti Maggiore U; Ferrero S
Expert Opin Biol Ther; 2016; 16(3):407-19. PubMed ID: 26796332
[TBL] [Abstract][Full Text] [Related]
14. Anti-angiogenic therapy for high-grade glioma.
Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
[TBL] [Abstract][Full Text] [Related]
15. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
16. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Cabebe E; Wakelee H
Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
[TBL] [Abstract][Full Text] [Related]
17. Clinical Trials of Antiangiogenesis Therapy in Recurrent/Persistent and Metastatic Cervical Cancer.
Alldredge JK; Tewari KS
Oncologist; 2016 May; 21(5):576-85. PubMed ID: 27026677
[TBL] [Abstract][Full Text] [Related]
18. The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer.
Minion LE; Tewari KS
Expert Rev Anticancer Ther; 2017 Mar; 17(3):191-198. PubMed ID: 27748633
[TBL] [Abstract][Full Text] [Related]
19. Improvements in progression-free and overall survival due to the use of anti-angiogenic agents in gynecologic cancers.
Schmid BC; Oehler MK
Curr Treat Options Oncol; 2015 Jan; 16(1):318. PubMed ID: 25750175
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer.
Friedman CF; Snyder Charen A; Zhou Q; Carducci MA; Buckley De Meritens A; Corr BR; Fu S; Hollmann TJ; Iasonos A; Konner JA; Konstantinopoulos PA; Modesitt SC; Sharon E; Aghajanian C; Zamarin D
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33004542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
